Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nucana Plc ADR
(NQ:
NCNA
)
1.230
-0.040 (-3.15%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nucana Plc ADR
< Previous
1
2
Next >
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
November 11, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
September 25, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
September 14, 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
August 29, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
May 21, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 01, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Completion of ADS Ratio Change
April 16, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
April 09, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Plan to Implement ADS Ratio Change
March 27, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
March 20, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana to Present at TD Cowen’s 44th Annual Health Care Conference
February 27, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
NuCana plc
Via
GlobeNewswire
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
November 16, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Listing Transfer to Nasdaq Capital Market
November 10, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium
November 01, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 16, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 13, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
September 18, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
August 16, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana to Present at the Jefferies Healthcare Conference
June 01, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
May 17, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Announces Receipt of Nasdaq Notice
May 12, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
April 14, 2023
From
NuCana plc
Via
GlobeNewswire
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
April 04, 2023
From
NuCana plc
Via
GlobeNewswire
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
March 24, 2023
Ruling Has No Impact on NuCana’s Anti-Cancer ProTide Patents
From
NuCana plc
Via
GlobeNewswire
NuCana to Participate in Two Upcoming Investor Conferences
February 28, 2023
From
NuCana plc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
